combinatorial chemistry

(redirected from Combichem)
Also found in: Encyclopedia, Wikipedia.

combinatorial chemistry

The branch of chemistry in which a few basic molecules are combined in various ways to yield a large number of different products; often undertaken in pharmaceutical research.

combinatorial chemistry

The science of creating chemical diversity, a chemistry-based platform for systematically assembling known chemical entities—molecular building blocks—in as many different combinations as possible, generating millions of new screenable compounds for rapid drug discovery. The strategy is to assemble every possible combination of a given set of chemical building blocks while simulataneously recording which ones have been used and in what order, then assay the resulting molecules at once and refer to the record to determine the identity of any that look promising.

Drugs developed by traditional synthetic chemistry require an average of 12 years to identify, while combinatorial compounds of potential interest may be identified within a month; most compounds thusfar created are peptides and oligonucleotides. In the pharmaceutical industry, combinatorial “libraries” of millions of compounds may be produced by smaller biotechnology companies, which may be purchased in part or their entirety by larger companies seeking leads for newer therapeutic agents.
 
Phases, CC research
Synthesis, distribution, inventorying, screening.

combinatorial chemistry

The manufacturing of molecules having specific sizes, shapes, or functional characteristics using computer-aided algorithms or design rules.
See also: chemistry
References in periodicals archive ?
Previously, Mr McCracken served senior corporate roles at Prometheus Laboratories, Diversa, GenStar Therapeutics, CombiChem and Allergan.
The era of combichem saw some of us attempt to skip too quickly to the last page, with concomitant loss of plot.
Through the discovery of compounds that interact with these targets, combichem is translating advances in genomics into real-life therapeutic solutions.
Using its proprietary Discovery Engine(TM) process, CombiChem focuses on the generation, evolution, and optimization of new lead candidates for its collaborative partners, who will then develop, manufacture, market, and sell the resulting products.
Chromagen will develop biological assays and screen CombiChem compounds, while receiving research support and a percentage of future payments received by CombiChem upon outlicensing of drug candidates.
Earlier in his career, he held leadership roles with GenStar Therapeutics, CombiChem and Allergan Americas.
Prior to this, he was general partner of Windamere Venture Partners, served as President and CEO of CombiChem, Inc.
She also previously held similar positions with CombiChem, Inc.
She has also served in similar senior level management roles at Combichem, Inc.
From 1996-1999 was president and CEO of CombiChem Inc.
She previously served as senior vice president of finance, chief financial officer, and secretary of Diversa Corporation and held senior management positions with CombiChem, Inc.